Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Fineline Cube Aug 10, 2026
Company Deals Drug

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Fineline Cube Aug 10, 2026
Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Fineline Cube Aug 10, 2026
Company Drug

Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials

Fineline Cube Aug 10, 2026
Company Deals

Zucara Therapeutics Secures $20M Series B Financing Led by Sanofi and PXV Fund

Fineline Cube Nov 14, 2024

Canada-based diabetes life sciences company, Zucara Therapeutics Inc., has announced the receipt of a strategic...

Company Drug

Novartis’ Pluvicto Accepted for Review by China’s NMPA for Prostate Cancer Treatment

Fineline Cube Nov 14, 2024

The Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) has accepted...

Company Drug

Daiichi Sankyo and AstraZeneca File BLA for Datopotamab Deruxtecan in NSCLC

Fineline Cube Nov 14, 2024

Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN), partners in the development of innovative...

Company Deals

Zhejiang Dian Diagnostics Partners with SNN/CRHA for Optic Nerve Disease Research

Fineline Cube Nov 14, 2024

China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostic solutions provider, has formed...

Company Deals

BioNTech Seals Acquisition of China’s Biotheus for Up to $950M

Fineline Cube Nov 14, 2024

China’s Biotheus Inc. has entered into a definitive acquisition agreement with Germany-based BioNTech SE (NASDAQ:...

Company Deals

Arctic Vision and Santen Ink Deal for ARVN001 Commercialization in China

Fineline Cube Nov 14, 2024

China-based ophthalmology specialist, Arctic Vision, has entered into a strategic collaboration with Japan’s Santen Pharmaceutical...

Company

Pfizer Considers Sale of Hospital Unit Amid Pressure from Starboard Value

Fineline Cube Nov 14, 2024

Pfizer Inc. (NYSE: PFE) is reportedly considering the sale of its hospital unit, Pfizer Hospital,...

Company

FibroGen Inc. Reports 15% YOY Revenue Growth in Q3 2024 Led by Evrenzo

Fineline Cube Nov 13, 2024

US-based biopharmaceutical company FibroGen Inc. (NASDAQ: FGEN) has released its Q3 2024 financial report, showing...

Company

AstraZeneca Inc. Reports 21% YOY Revenue Growth in Q3 2024 Financials

Fineline Cube Nov 13, 2024

UK-based pharmaceutical giant AstraZeneca Inc. (AZ, NASDAQ: AZN) has reported its financial performance for the...

Company

BeiGene’s Q3 2024 Results Show 28% YOY Revenue Growth Driven by Brukinsa and Tevimbra

Fineline Cube Nov 13, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a China-based biotech company, has released its...

Company

Bayer AG Posts Modest Q3 Growth with Strong Performance from New Pharmaceuticals

Fineline Cube Nov 13, 2024

Germany-based Bayer AG (ETR: BAYN) has released its Q3 2024 financial results, reporting a 0.6%...

Company Deals

Sunshine Lake Pharma Inks Licensing Deal with Apollo Therapeutics for APL-18881

Fineline Cube Nov 13, 2024

China-based Sunshine Lake Pharma Co., Ltd., (HKG: 1558) a member of the HEC Group, has...

Company Deals

Sihuan Pharmaceutical Plans IPO for Xuanzhu Biopharm on Hong Kong Stock Exchange

Fineline Cube Nov 13, 2024

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced a renewed attempt to spin...

Company Deals

Boehringer Ingelheim Joins MTM Vision Consortium to Advance Diabetes Retinopathy Research

Fineline Cube Nov 13, 2024

Germany-based pharmaceutical major Boehringer Ingelheim has announced the initiation of a long-term collaboration with the...

Company Medical Device

J&J MedTech Receives FDA IDE for OTTAVA Robotic Surgical System Trials

Fineline Cube Nov 13, 2024

US-based Johnson & Johnson MedTech (J&J, NYSE: JNJ) has announced that it has received an...

Company

Zai Lab Ltd Reports 46% YOY Revenue Growth in Q3 2024 Driven by Vygart, Zejula, and Nuzyra

Fineline Cube Nov 13, 2024

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its Q3 2024 financial...

Company

Legend Biotech’s Q3 Revenue Soars 67% YOY Driven by Carvykti Sales

Fineline Cube Nov 13, 2024

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced its financial results for the third quarter...

Company Deals

Canhelp Genomics Partners with Mirxes to Expand Tumor Origin Testing in Southeast Asia

Fineline Cube Nov 13, 2024

Canhelp Genomics, a Chinese company specializing in oncology-focused molecular diagnostics, has formed a strategic partnership...

Company Deals

Vesalius Therapeutics Partners with GSK for Novel Parkinson’s Disease Treatments

Fineline Cube Nov 13, 2024

US-based Vesalius Therapeutics has entered into a strategic agreement with UK pharmaceutical giant GSK plc...

Company Deals

Flare Therapeutics and Roche Enter Strategic Collaboration for Oncology Drug Discovery

Fineline Cube Nov 13, 2024

US-based Flare Therapeutics Inc., a clinical-stage biotech company specializing in cancer therapies through the use...

Posts pagination

1 … 307 308 309 … 705

Recent updates

  • GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled
  • Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor
  • WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation
  • Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials
  • Grand Pharma’s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Legal / IP

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Company Drug

Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.